BioSpace News Archive

Adicet Bio, Inc. today announced the appointment of Michael G. Kauffman, M.D., Ph.D., to its Board of Directors.

FDA Approves Merck’s KEYTRUDA ® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery.

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), today announced that John H. Sampson, MD, PhD, MHSc, MBA, Robert H. and Gloria Wilkins Distinguished Professor of Neurosurgery at Duke University School of Medicine and member of Medicenna’s Board of Directors, received The Abstract Award for Excellence in Clinical Trials in connection with an upcoming oral presentation on MDNA55.

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics to improve surgical outcomes, announced today that the 500th patient has been enrolled into its ongoing Phase 3 SHIELD I study.

Proceeds will fund the continued clinical development of CFI-400945, CFI-402257 and CFI-402411, the preclinical development of the Biologics and Cell Therapy platform.

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced that Chairman, President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at Evercore ISI’s 4th Annual HealthCONx Conference on Thursday, December 2, 2021, at 1:00 p.m. Eastern Time.

CollPlant Biotechnologies today announced business updates and financial results for the third quarter ended September 30, 2021.

Schrödinger will receive $4.9 million research grant from the Bill & Melinda Gates Foundation to support early-stage drug discovery of non-hormonal contraceptives.

Altay Therapeutics, RADD Pharmaceuticals, Rubik Therapeutics, VastBiome and Waypoint Bio to receive free year of lab bench use and other amenities at prominent bioscience incubators.

Avilar Therapeutics today announced a $60 million seed financing from founding investor RA Capital Management.